Scientific deep-dive

Ozempic Side Effects (2026): What's Common, What's Serious & How to Manage Them

The common GI side effects of Ozempic (semaglutide) — nausea, diarrhea, vomiting, constipation, abdominal pain — plus serious risks (pancreatitis, gallbladder, kidney injury, hypoglycemia, ileus, vision changes) and the thyroid boxed warning. Verified against the FDA DailyMed label §6.

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed
11 min read·4 citations

The most common Ozempic side effects are gastrointestinal and usually mild-to-moderate: nausea, diarrhea, vomiting, constipation, and abdominal pain, driven by how the drug slows the gut. In the Ozempic clinical trials, nausea was the single most frequent reaction at roughly 15-20% of patients, generally heaviest right after each dose increase and easing as the body adapts.[1] A smaller number of effects are serious and warrant prompt medical attention — pancreatitis, gallbladder disease, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or a sulfonylurea), intestinal blockage (ileus), and worsening diabetic eye disease — and Ozempic carries an FDA boxed warning for the risk of thyroid C-cell tumors based on rodent studies.[1] This guide separates what is common and expected from what is rare and serious, explains why the GI effects happen and how slow titration reduces them, and lays out exactly when to call your prescriber. Ozempic is semaglutide; see our Ozempic drug page and the semaglutide dosage chart for the titration schedule that drives much of the tolerability picture. This is general educational information, not medical advice — your prescriber manages your care.

About this article

Every adverse-event figure below was verified against the FDA prescribing label for Ozempic on DailyMed (NIH) — §6 "Adverse Reactions" and the §5 Warnings and Precautions — plus the SUSTAIN trial program, not an AI paraphrase or a third-party drug-monograph site. The most common reactions (nausea, vomiting, diarrhea, abdominal pain, constipation) and their approximate incidence are taken from the label's pooled placebo-controlled trial tables. The cardiovascular and diabetic-retinopathy data come from SUSTAIN-6 (Marso et al., N Engl J Med 2016, PMID 27633186), confirmed by direct PubMed lookup. Reported rates vary by dose, trial population, and whether semaglutide is combined with insulin or a sulfonylurea, so treat the percentages as approximate. For the dosing context, see the semaglutide dosage chart and the Ozempic drug page. This is general information, not medical advice.

Boxed warning — risk of thyroid C-cell tumors

Ozempic carries an FDA boxed warning: in rodent studies, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (including medullary thyroid carcinoma). It is unknown whether Ozempic causes such tumors in humans. Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell any patient about the potential risk and the symptoms of thyroid tumors — a neck mass, trouble swallowing, persistent hoarseness, or shortness of breath. This box is the most serious warning the FDA can place on a label; the sections below cover the full risk profile.[1]

The most common side effects

By a wide margin, the most common Ozempic side effects are gastrointestinal. In the placebo-controlled clinical trials summarized in the FDA label §6, the reactions reported most often were nausea, vomiting, diarrhea, abdominal pain, and constipation.[1] These are typically mild to moderate, are most pronounced in the first weeks and right after each dose increase, and tend to ease over time as the body adapts.

  • Nausea — the most common reaction, reported by roughly 15-20% of patients in trials (more frequent at the higher 1 mg dose than at 0.5 mg). Usually transient and dose-related.[1]
  • Diarrhea — common, on the order of ~8-9% of patients, again more frequent at higher doses.[1]
  • Vomiting — reported by roughly ~5-9% of patients, clustering around dose escalations.[1]
  • Abdominal pain — affecting roughly ~6-7% of patients.[1]
  • Constipation — roughly ~3-5% of patients; the flip side of the same gut-slowing mechanism that can cause diarrhea in others.[1]

Other reactions seen more often than with placebo include dyspepsia (indigestion), eructation (burping), flatulence, gastroenteritis, and gastroesophageal reflux, along with decreased appetite — which for a weight or glycemic-control medication is partly the intended effect rather than a true adverse event.[1] The table and chart below put the headline GI rates side by side against placebo so you can see how much of each is drug-attributable.

Most common adverse reactions reported in the Ozempic placebo-controlled clinical trials (approximate pooled incidence, 0.5 mg and 1 mg once weekly vs placebo). Figures are approximate and rounded; exact rates vary by dose and trial. Verified against the FDA DailyMed Ozempic label §6.
Adverse reactionOzempic 0.5 mg (approx.)Ozempic 1 mg (approx.)Placebo (approx.)
Nausea~16%~20%~6%
Vomiting~5%~9%~2%
Diarrhea~9%~9%~2%
Abdominal pain~6%~7%~5%
Constipation~5%~3%~2%

Magnitude comparison

Approximate incidence of the most common gastrointestinal side effects of Ozempic (1 mg once weekly) in placebo-controlled trials, percent of patients. GI reactions dominate the side-effect profile and are dose-related. Figures are approximate, pooled, and rounded; verified against the FDA DailyMed Ozempic label §6.[1]

  • Nausea20 % of patients
    most common reaction; heaviest after dose increases
  • Vomiting9 % of patients
    clusters around titration steps
  • Diarrhea9 % of patients
    dose-related; usually transient
  • Abdominal pain7 % of patients
    typically mild to moderate
  • Constipation3 % of patients
    the flip side of slowed gut transit
Approximate incidence of the most common gastrointestinal side effects of Ozempic (1 mg once weekly) in placebo-controlled trials, percent of patients. GI reactions dominate the side-effect profile and are dose-related. Figures are approximate, pooled, and rounded; verified against the FDA DailyMed Ozempic label §6.

Why the GI effects happen — and how titration reduces them

Semaglutide is a GLP-1 receptor agonist, and the gastrointestinal side effects are a direct consequence of how it works rather than a quirk to be surprised by. GLP-1 receptor activation slows gastric emptying (food leaves the stomach more slowly), acts on appetite and satiety signaling in the brain, and influences gut motility. Slowed gastric emptying and altered motility are exactly what produce nausea, fullness, vomiting, and the constipation-or-diarrhea swing. Because these effects scale with dose, they are most intense when the dose goes up.[1]

This is the entire reason Ozempic is titrated slowly. The label starts every patient at 0.25 mg once weekly for four weeks — a dose that is explicitly non-therapeutic, included only to improve gastrointestinal tolerability — before stepping up to 0.5 mg, then (if needed) 1 mg, and a maximum of 2 mg, holding at least four weeks at each rung.[1] Starting low and climbing gradually lets the gut adapt to each dose before the next increase, which is why the nausea that hits hardest in the first weeks usually fades. The practical takeaway: rushing the schedule predictably worsens GI side effects, and when a dose is not tolerated, the label's move is to delay the next step up rather than push through. The full schedule is laid out in our semaglutide dosage chart, and you can preview the typical symptom arc with the GLP-1 side-effect timeline.

Serious but less common side effects

Beyond the common GI reactions, the Ozempic label §5 lists several serious but less common risks. These are uncommon, but each warrants awareness because some require stopping the drug and seeking care. None of this is a reason to fear the medication — it is the reason Ozempic is a prescription drug taken under medical supervision rather than something you self-manage.

  • Pancreatitis (inflammation of the pancreas). Acute pancreatitis, including fatal and non-fatal cases, has been reported. If pancreatitis is suspected, Ozempic should be discontinued. Warning signs: severe, persistent abdominal pain that may radiate to the back, sometimes with vomiting.[1]
  • Gallbladder disease (cholelithiasis). Gallstones and acute gallbladder inflammation have occurred, partly linked to rapid weight loss. Symptoms include upper-right abdominal pain, fever, jaundice (yellowing of skin or eyes), and clay-colored stools.[1]
  • Acute kidney injury (AKI). Reported, mostly in the setting of nausea, vomiting, and diarrhea leading to dehydration and reduced kidney perfusion; it can worsen pre-existing kidney disease. Staying hydrated during GI side effects matters.[1]
  • Hypoglycemia (low blood sugar). Ozempic on its own carries a low risk of hypoglycemia, but the risk rises substantially when it is combined with insulin or an insulin secretagogue such as a sulfonylurea. With those combinations, the dose of the secretagogue or insulin may need to be lowered.[1]
  • Ileus (intestinal blockage). Postmarketing reports led to ileus being added to the label. Symptoms include severe constipation, abdominal distension and pain, and persistent nausea/vomiting; it can require urgent care.[1]
  • Diabetic retinopathy complications / vision changes. In the SUSTAIN-6 cardiovascular outcomes trial, complications of diabetic retinopathy were more frequent with semaglutide than placebo in patients with a history of diabetic eye disease.[2] Any sudden change in vision should be reported promptly. The FDA has also been evaluating a postmarketing safety signal for NAION (non-arteritic anterior ischemic optic neuropathy), a rare cause of sudden vision loss, reported with semaglutide; the relationship is still under review and not established as causal.
  • Serious allergic reactions (hypersensitivity). Anaphylaxis and angioedema have been reported. Stop Ozempic and seek care for swelling of the face/lips/tongue/throat, difficulty breathing, or a severe rash.[1]

The boxed warning: thyroid C-cell tumors

Ozempic's single most serious warning is its FDA boxed warning (the strongest warning the FDA issues) for the risk of thyroid C-cell tumors. In two-year studies in rats and mice, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma, at clinically relevant exposures.[1]

The critical nuances: this finding is from rodent studies, and it is not known whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans — the human relevance of the rodent signal has not been determined. Because of it, Ozempic is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1] Patients should be counseled on the symptoms of thyroid tumors — a lump or mass in the neck, hoarseness, trouble swallowing, or shortness of breath. This is why a legitimate prescriber screens your personal and family thyroid history before starting Ozempic; a source that skips that screening is a safety red flag.

How to manage the common side effects

The GI side effects are usually manageable, and most strategies are about working with the slow-titration design rather than against it. The following are general, commonly-discussed approaches — all of them are prescriber-directed, and you should not change your dose, add medications, or stop Ozempic without talking to your clinician.

  • Respect the titration schedule. Most nausea spikes right after a dose increase and settles within days to weeks. If a rung is rough, your prescriber can keep you on the current dose longer before stepping up — slower is allowed; faster is not.[1]
  • Eat smaller, slower, lower-fat meals. Because the stomach empties more slowly on semaglutide, large or greasy meals tend to worsen nausea and fullness. Smaller portions, eating slowly, and stopping at "satisfied" rather than "full" usually help.
  • Stay hydrated — especially if you have vomiting or diarrhea. This is not just comfort: dehydration from GI symptoms is the main pathway to the acute kidney injury risk above, so keeping fluids up is a genuine safety measure.[1]
  • Manage constipation actively. Adequate fluids, dietary fiber, and movement help; your prescriber may suggest an over-the-counter option. Persistent severe constipation with abdominal distension can be a sign of ileus and should be reported, not just self-treated.
  • Ask your prescriber about anti-nausea support. For some patients, clinicians prescribe a short course of an anti-nausea medication around dose increases — a decision for your prescriber, not a self-treatment.
  • Watch interacting medications. If you also take insulin or a sulfonylurea, your prescriber may lower those doses to reduce hypoglycemia risk; don't adjust them on your own.[1]

For where you give the injection and how that fits the weekly routine, see where to inject Ozempic and Wegovy. To map your dose-escalation dates against the typical symptom arc, use the GLP-1 side-effect timeline.

When to call your provider — or stop and seek urgent care

Most Ozempic side effects are mild and self-limiting, but a defined set of symptoms means contact your prescriber promptly, and some mean stop and seek urgent/emergency care. Use this as a general guide, not a substitute for your clinician's instructions, and when in doubt, call.

  • Seek emergency care for signs of a serious allergic reaction: swelling of the face, lips, tongue, or throat, trouble breathing, or a severe spreading rash.[1]
  • Seek urgent care for severe, persistent abdominal pain (especially radiating to the back, with or without vomiting) — a possible sign of pancreatitis — and stop Ozempic until evaluated.[1]
  • Seek urgent care for severe constipation with abdominal swelling, persistent vomiting, and inability to pass stool or gas — possible ileus.[1]
  • Call your prescriber promptly for upper-right abdominal pain, fever, or yellowing of the skin/eyes — possible gallbladder disease — and for sudden vision changes.[1][2]
  • Call your prescriber if vomiting or diarrhea is severe enough that you can't keep fluids down, to head off dehydration and kidney injury — and treat low-blood-sugar symptoms (shakiness, sweating, confusion, fast heartbeat) per your clinician's plan, especially if you also use insulin or a sulfonylurea.[1]
  • Report any neck lump or mass, hoarseness, trouble swallowing, or shortness of breath — the thyroid-tumor symptoms tied to the boxed warning.[1]

If you are evaluating where to start or continue treatment under proper medical supervision, compare the best semaglutide providers, or read our reviews of Found and Ro. A legitimate provider screens you for the contraindications above, titrates you on the label schedule, and follows up on side effects — exactly the monitoring that keeps Ozempic's risk profile manageable.

References

  1. 1.Novo Nordisk Inc. OZEMPIC (semaglutide) injection, for subcutaneous use — US Prescribing Information, §6 Adverse Reactions, §5 Warnings and Precautions, and Boxed Warning (risk of thyroid C-cell tumors). DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. 2.Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — including the diabetic-retinopathy-complications finding. N Engl J Med. 2016. PMID: 27633186.
  3. 3.US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) and postmarket drug safety communications — semaglutide, including ileus labeling and the NAION (vision loss) signal under evaluation. FDA. 2025. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers
  4. 4.Novo Nordisk Inc. OZEMPIC (semaglutide) — Medication Guide (patient-facing summary of risks: thyroid tumors, pancreatitis, gallbladder problems, kidney injury, allergic reactions, low blood sugar, and vision changes). DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

Where to get semaglutide (Ozempic / Wegovy): vetted providers

Vetted telehealth providers that prescribe online, ranked by our editorial score. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.6

MEDVi

Patients who want the option to switch between compounded and brand-name GLP-1 through one provider

7.4

ShedRx

Mainstream telehealth GLP-1 access

7.4

Synergy Rx

Broadest drug catalog in the Lion MD white-label cluster